Helios Technologies (HLIO) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
8 Jul, 2026Executive summary
Q2 2024 net sales were $219.9M, down 3% year-over-year but up 4% sequentially, with Hydraulics up 2% and Electronics up 7% from Q1 2024.
Diluted EPS was $0.41 (GAAP) and $0.64 (Non-GAAP), with Non-GAAP EPS up 21% sequentially but down year-over-year.
Cash from operations reached $33.8M in Q2, up 30% year-over-year and 90% sequentially; cash on hand at quarter-end was $45.0M.
Management focus remains on margin protection, cash generation, debt reduction, and operational efficiency amid leadership transition.
Outlook for 2H24 moderated due to softening end market conditions, with continued emphasis on cost discipline and customer service.
Financial highlights
Q2 2024 net sales: $219.9M (down 3% year-over-year); gross margin: 32.1% (down 120 bps); operating income: $26.0M (11.8% margin, down 12%).
Adjusted EBITDA margin was 20.1%, up 190 bps sequentially but down 190 bps year-over-year.
Net income for Q2 was $13.6M, down 19% year-over-year; free cash flow for Q2 was $25.7M.
Inventory reduced by 4% since year start; capital expenditures were $8.1M (3.7% of sales).
Net debt leverage ratio reduced to 3.0x, with total debt down 4% from year-end 2023.
Outlook and guidance
Full-year 2024 net sales guidance revised to $825–$840M, reflecting macro headwinds and lower order demand.
Adjusted EBITDA margin guidance maintained at 19.5%–21%; non-GAAP EPS expected at $2.25–$2.45.
Q3 sales expected at $192–$200M, with adjusted EBITDA margin of 20%–21%.
Capital expenditures for 2024 forecasted at 3.5%–4.0% of sales; effective tax rate expected at 21%–23%.
Hydraulics segment revenue expected to decline 1%–3% year-over-year; Electronics segment to grow 2%–4%.
Latest events from Helios Technologies
- Strong 3Q25 growth and innovation drive a positive 2025 outlook, supported by a diversified portfolio.HLIO
Investor presentation13 Jul 2026 - Q1 2025 sales fell 8% YoY, but cash flow, margins, and debt reduction remained strong.HLIO
Q1 20258 Jul 2026 - Transformation, margin expansion, and operational resilience drive future growth.HLIO
Baird 2024 Global Industrials Conference8 Jul 2026 - Imminent ARDS therapy launch in Japan and global phase III trial signal major growth ahead.HLIO
Jefferies Global Healthcare Conference 202611 Jun 2026 - Q1 2026 sales up 17% with record margins, cash flow, and a raised full-year outlook.HLIO
Q1 202618 May 2026 - Director elections, auditor ratification, and equity plan amendment up for shareholder vote.HLIO
Proxy filing7 May 2026 - Growth, governance, and sustainability drive key proposals and leadership changes for 2026.HLIO
Proxy filing4 May 2026 - Record Q4 and FY25 results, margin gains, and cash flow set up continued growth in FY26.HLIO
Q4 202527 Apr 2026 - Core 2030 targets $1.6B sales, 25%+ EBITDA margin, and accelerated innovation by 2030.HLIO
Investor Day 202620 Mar 2026